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Available online xxxxBone protective effects of TNFα inhibition in rheumatoid arthritis are thought to bemediated by inhibiting syno-
vial osteoclast differentiation and activity. However, it has not been addressed, if TNFα inhibitors alter the pool of
peripheral osteoclast precursor cells (OPCs). Here, we blocked TNFα function in C57BL/6 mice with antigen in-
duced arthritis (AIA) using the soluble TNFα receptor etanercept. Synovial bone lesions and osteoclasts were
markedly reduced upon Etanercept in the early chronic phase of AIA. Unexpectedly this was not associated
with a reduced recruitment of circulating OPCs to the arthritic joint nor to reduced synovial inﬂammation. In con-
trast we found that OPC numbers in bone marrow and blood were signiﬁcantly reduced. Overall our study sug-
gests that arrest of osteoclastmediated bone lesions upon inhibition of TNFα is, at least initially, based on reduced
OPC availability in the periphery, and not on OPC recruitment or local anti-inﬂammatory effects in the arthritic
joint.
© 2017 Elsevier Inc. All rights reserved.Keywords:
Arthritis
Blockade of TNFα
Bone protection
Osteoclast precursors1. Introduction
Inﬂammation-induced bone lesions are a key feature in human
rheumatoid arthritis (RA) and animal models of chronic arthritis [1,2].
The differentiation of new bone resorbing osteoclasts in the arthritic
joint critically depends on two essential factors: Macrophage colony
stimulating factor (M-CSF) and receptor activator of NF-κB ligand
(RANKL) [3,4]. An additional requirement for synovial osteoclastogene-
sis is the availability of OPCs, which belong to the monocyte/macro-
phage lineage [5]. Monocytes are divided into two subsets, classical
and non-classical monocytes, which in mice, can be distinguished byAP, tartrate resistant acidic
acrophage colony stimulating
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ork.their Ly6ChighCX3CR1inter and Ly6ClowCX3CR1high marker expression,
respectively [6]. After maturation in the bone marrow, classical and
non-classical monocytes circulate in blood and become inﬂammatory
macrophages upon recruitment to the site of inﬂammation. These inﬁl-
tratingmonocyte-derivedmacrophages are potent producers of pro-in-
ﬂammatory cytokines and efﬁciently initiate immune responses [7,8]. In
contrast, tissue residentmacrophages are considered to bemore impor-
tant for the maintenance and restoration of tissue integrity. Due to self-
proliferation, they maintain themselves mostly independently of newly
recruited hematopoietic cells [9,10].
In RA, inﬂamed joints provide an optimal environment for the differ-
entiation of bone resorbing osteoclasts [11]. On one side, M-CSF and
RANKL expression is induced by the high level of pro-inﬂammatory cy-
tokines [12,13]; on the other side, continuous inﬁltration of circulating
monocytes into the inﬂamed synovial compartment provides a cell
pool that is prone to differentiate into osteoclasts. The bone protective
effect mediated by blockade of TNFα is well known and mostly ex-
plained by attenuation of inﬂammatory processes, favoring osteoclasto-
genesis within the arthritic joint [14,15,16]. However, there is emerging
evidence, that anti-TNFα therapy affects osteoclastogenesis outside of
the synovial compartment. TNFα has been associated with alterations
in the pool of peripheral OPCs [17]. Furthermore, patients that were
treated with TNFα inhibitors showed a bone protective effect that was
not dependent on the inﬂammation in the arthritic joint [18]. Although
57S. Uster et al. / Bone 107 (2018) 56–65myeloidmarkerswere previously used to characterize OPC populations,
the precise distinction between different monocyte subsets was often
not completely taken into consideration [17,19].
In the present study, we used heterozygous CX3CR1-GFP knock-in
mice and attributed an osteoclastogenic potential to the classical Ly6C-
highCX3CR1inter monocyte subset.We demonstrate that in an AIAmouse
model TNFα inhibition reduced availability of these OPCs in bone mar-
row and blood without affecting their recruitment to the still highly in-
ﬂamed joint.
2. Materials and methods
2.1. Animals and experimental arthritis model
C57BL/6J mice were obtained from Janvier (Genest Saint Isle,
France). CX3CR1-GFP knock-inmice (Cx3cr1tm1Litt) were kindly provid-
ed by Israel F. Charo (Gladstone Institute of Cardiovascular Research,
University of California, San Francisco, USA). TNFR1/2 −/− (B6.129S-
Tnfrsf1atm1lmxTnfrsf1btm1lmx/J) mice were obtained from Jackson Labo-
ratory (Bar Harbor, Maine, USA). All mouse lines were backcrossed to
C57BL/6J background for at least eight generations. Mice were housed
in individually ventilated cages under speciﬁc pathogen-free conditions
with water and food ad libitum. Animal procedures were performed in
accordance with the Swiss legislation on the protection of animals and
were approved under the application number BE 18/12 and BE 55/15
by the veterinary ofﬁce of the Canton of Bern.
AIA was induced in 6–8 weeks old female mice using a previously
described protocol [20]. Brieﬂy, micewere immunized by subcutaneous
injection of 100 μg methylated bovine serum albumin (mBSA) (Sigma)
in complete Freund's adjuvant (CFA) on day-21 and in incomplete
Freund's adjuvant (IFA) (Santa Cruz Biotechnology, Inc) on day-14.
CFAwas additionally supplementedwith 4mg/ml heat-killedMycobac-
terium tuberculosis strain H37RA (Becton, Dickinson and Company). In
parallel to each immunization, 200 ng of Bordetella pertussis toxin (List
biological laboratories, Inc., Campbell, CA, USA) was administrated by
an intraperitoneal injection. Arthritis was induced by injecting 100 μg
ofmBSA in 20 μl physiologic saline into the knee joint, whereas injection
of saline was used as sham control for the contralateral knee. 10 mg/kg
of etanercept (Enbrel®, Pﬁzer) or human polyclonal IgG (BioXCell) was
subcutaneously injected every other day after arthritis induction.
2.2. Adoptive transfer of monocytes
Monocytes were isolated from bone marrow and enriched by using
CD115 MicroBead kit (MACS, miltenyibiotec). Cells were labeled with
CSFE (Thermoﬁsher, 1:1000 dilution) at 37 °C for 20 min. 5 × 106 cells
were injected via the femoral artery into AIA WT mice on day 14.
After 30–60 min, periarticular tissue was harvested and recruitment of
CD45highCD11b+CSFE+ monocytes was quantiﬁed by ﬂow cytometry.
2.3. Flow cytometry of bone marrow, blood and periarticular cells
200 μg bromodeoxyuridine (BrdU) was intravenously injected and
micewere euthanized after 30min. Usingﬂow cytometry, local cell pro-
liferation was analyzed by BrdU incorporation in cells from femora and
periarticular tissues. Cell surface staining was performed for 1 h at 4 °C.
For additional intracellular BrdU staining, cells were incubated in
Cytoﬁx/Cytoperm Buffer (BDBioscience). Cells were kept in 10% DMSO
at−80 °C. After thawing, cells were reﬁxed and treated with 300 μg/
ml DNAse for 1 h at 37 °C and stained for BrdU. Total blood count was
determined with a scil VetABC™ Hematology Analyzer (Scil animal
care company, Viernheim, Germany). Total cell count of bone marrow
and periarticular tissue was determined by using PKH26 reference
microbeads (Sigma). Samples were measured with the LSR II
(BDBioscience) and data were analyzed with the FlowJo software.2.4. Monocyte sorting and in vitro osteoclast cultures
Bone marrow cells were harvested from CX3CR1-GFP knock-in
mice and stained with anti-CD117 antibody. Non-classical mono-
cytes were deﬁned as CX3CR1-GFPhighCD117− and classical mono-
cytes as CX3CR1-GFPinterCD117−. For sorting from blood, non-
classical and classical monocytes were deﬁned by their CX3CR1-
GFPhigh and CX3CR1-GFPinter expression, respectively, and blood
from mice with on-going arthritis from AIA day 3 was used. Sorting
was performed by using ARIA ﬂow cytometry (BDBioscience).
30`000 cells were distributed in a 48-well plate and cultured in
complete α-MEM medium supplemented with 30 ng/ml M-CSF
and 50 ng/ml RANKL at 37 °C. After 5 days for bone marrow and
after 14 days for blood cultures, cells were ﬁxed, stained for TRAP
(Sigma) and the number of multinucleated TRAP+ osteoclasts/
well was determined.2.5. Histology, immunohistochemistry and microCT
Mice were perfused with 4% PFA and knee joints were harvest-
ed. After overnight post-ﬁxation, knees were decalciﬁed in 15%
EDTA and parafﬁn embedded. One section of each knee was sagit-
tally cut through the center of the joint and stained with H&E and
for TRAP, respectively. Synovial inﬂammation on H&E stained
knee sections were scored as followed: perivascular leukocyte in-
ﬁltration (0–5), synovial leukocyte inﬁltration (0–5), synovial hy-
perplasia (0–5). Bone parameters on H&E knee sections were
scored by bone erosion severity on meniscus (0–4) and tibial
joint surface (0–4). Synovial osteoclasts on TRAP stained knee sec-
tions was scored by TRAP+ osteoclasts located on the meniscus (0–
3) and tibial bone surface (0–3). For immunohistochemistry, knee
sections were incubated for 1 h with primary rat and secondary
rabbit anti-rat antibody. A system-HRP labeled polymer anti-rabbit
(Envision Dako) was added for 30 min on parafﬁn sections. Sec-
tions were washed and incubated in the substrate solution with
AEC tablets. F4/80 and Gr-1 staining was scored by intensity (0–
5) in the complete synovial compartment and the bone surface
area. Undecalciﬁed tibia from CX3CR1-GFP knock-in mice were
sectioned by using the CryoJane Tape-Transfer System (Leica) ac-
cording to Jiang et al. [21]. MicroCT analysis was done 14 days
after arthritis onset in IgG (n = 4) and etanercept (n = 4) treated
mice.2.6. Serum chemokines in non-arthritic and arthriticmicewith andwithout
etanercept treatment
Circulating chemokines fromnon-arthritic aswell as arthriticmicewith
and without anti-TNF treatment with etanercept weremeasured in serum
14 days after onset of arthritis. For this purpose a membrane – based anti-
body array/sandwich immunoassay from R&D Systems (Bio – Techne AG,
Zug, Switzerland) was used to detect 25 chemokines in mouse serum
samples.2.7. Antibodies for ﬂow cytometry
All rat anti-mouse monoclonal antibodies used for ﬂow cytome-
try were purchased from BioLegend: anti-Ly6G (18A), anti-CD45
(30-F11), anti-CD115 (AFS98), anti-CD117 (2B8), anti-CD11b
(M1/70), anti-Ly6C (HK1.4), anti-BrdU (Bu20a), anti-NK1.1
(PK136), anti-B220 (RA3-6B2), anti-CD19 (6D5), anti-SiglecF
(E50-2440), anti-CD90.2 (30-H12), IgG1, κ (RTK2071), IgG2a, κ
(RTK2758), IgG2b, κ (RTK4530). Negative controls were done
with unspeciﬁc isotype antibodies.
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Rat anti-mouse F4/80 (clone CI:A3–1, produced in house). Rat anti-
mouse Gr-1 (NIMP-R14, Abcam). Rat IgG2b, κ (RTK4530, BioLegend).2.9. Statistical analyses
Statistical analysis was performed using GraphPad Prism 6.0 software
(Graphpad software, La Jolla, CA, USA). Data were compared by Mann-Fig. 1. Inﬁltration of leukocytes and monocytic osteoclast precursors into the arthritic knee is
cellularity of non-inﬂamed sham knee (left) and arthritic knees from AIA day 3 (center) and
histological scoring of synovial inﬂammation of sham group (n = 3 mice) and of AIA day 3 a
analyzed over arthritis course by ﬂow cytometry. Contour plots show CD45 vs. SSC with per
leukocytes (colored gates), respectively, in uninﬂamed sham knees (left) and arthritic knees f
from a single experiment (n= 4 mice) representative of two experiments performed. C) TRA
from AIA day 3 (center) and day 14 (right).➔ (synovial osteoclasts) Scale bar = 200 μm. Gra
day 14 groups (n = 5 mice each). D) Cellularity of periarticular tissues was analyzed by ﬂo
Contour plots illustrate gating strategy for CD45highCD11b+Linneg monocytes/macrophages. C
were gated on. Lineage markers = CD19, B220, NK1.1, Ly6G, Thy1, SiglecF. Numbers of inﬁ
experiments performed.Whitney test. Asterisks indicate signiﬁcant differences (*P b 0.05, **P b
0.01 and***P b 0.001, ****P b 0.0001).
3. Results
3.1. Antigen-induced arthritis leads to recruitment of monocytic osteoclast
precursors and osteoclastogenesis in inﬂamed knees
In order to investigate if TNFα affects synovial osteoclastogenesis on
the level of osteoclast precursors, we chose AIA as an animal model inassociated with the appearance of synovial osteoclasts. A) H&E staining shows synovial
day 14 (right).➔ (synovial inﬁltrates), x (pannus). Scale bar = 200 μm. Graph shows
nd day 14 groups (n = 5 mice each). B) Leukocyte cellularity of periarticular tissue was
centage of tissue resident CD45inter myeloid cells (black gates) and inﬁltrating CD45high
rom AIA day 3 (center) and day 14 (right). Numbers of inﬁltrating leukocytes are shown
P staining on parafﬁn sections shows osteoclasts in sham knee (left) and arthritic knees
ph shows histological scoring in knees of sham group (n= 2 mice) and of AIA day 3 and
w cytometry and the number of inﬁltrating monocytes/macrophages was determined.
olored gates in SSC vs. CD45 and CD11b vs. Lin plot highlight leukocyte populations that
ltrating macrophages are from a single experiment (n = 4 mice) representative of two
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continuous recruitment of circulating leukocytes/osteoclast precursors.
The antigen injection into the knee cavity of mice that were previously
two times immunized with adjuvants-antigen solutions, led to a
marked increase in synovial cellularity as determined by histology of
the knee joint already at day 3 post knee-injection. In the early chronic
phase of AIA, 14 days after knee-injection, synovial histopathology was
additionally associated with pannus formation and alterations in joint
architecture (Fig. 1A). Analysis by ﬂow cytometry of periarticular tissue
revealed two different CD45+ leukocyte populations in knee joints of
sham-treated and AIA mice. While non-inﬂamed knee joints of sham-
treated mice only harbored tissue resident CD45inter cells, periarticular
tissues of arthritic knees showed inﬁltration of CD45high leukocytes
(Fig. 1B, left). The total number of these inﬁltrating CD45high leukocytes
increased in arthritic knees from AIA day 3 to 14 (Fig. 1B, right). As a
next step, we investigated whether inﬁltration of CD45high leukocytes
was associated with the appearance of new bone resorbing osteoclasts.
In contrast to the osteoclast-free synovium of uninﬂamed sham knees
and arthritic knees from day 3, TRAP+ osteoclasts were found adjacent
to tibial bone lesions in the early chronic phase on day 14 of AIA (Fig.
1C). We hypothesized that the presence of synovial monocytes/macro-
phages was prerequisite for the observed osteoclastogenesis in the ar-
thritic joint on day 14. We deﬁned synovial monocyte/macrophages as
CD45highCD11b+ Lineageneg cells since it has been shown that the re-
cruitment of monocytic osteoclast precursors from the blood to the
knee joint rapidly induces expression of complex marker sets related
to tissue macrophage differentiation [8]. By using the gating strategy
shown in the FACS plots in Fig. 1D (left), the amount of synovial mono-
cytes/macrophages was quantiﬁed in the acute and early chronic phase
of AIA. Indeed, increased inﬁltration of these osteoclast precursor cells
correlated with the appearance of synovial osteoclasts and structural
damage in the knee joint on day 14 of AIA (Fig. 1D, right).
3.2. Classical monocytes rather than non-classical monocytes exhibit
osteoclastogenic properties
We observed in the early chronic phase of AIA, 14 days after arthritis
induction, osteoclast-mediated bone resorption, which was associated
with inﬁltration of monocytes/macrophages. This suggested that re-
cruitment of monocytic osteoclast precursors substantially contributed
to these new synovial bone lesions. To investigatewhichmonocyte sub-
sets hold the potential to differentiate into osteoclasts, we took advan-
tage of CX3CR1-GFP knock-in mice, in which CX3CR1 promoter
activity drives expression of GFP and thus allows distinction of classical
and non-classical monocytes.We conﬁrmed that classical CX3CR1-GFP-
inter and non-classical CX3CR1-GFPhigh bone marrow monocytes
expressed monocytic markers such as CD11b and CD115 (Supplemen-
tary Fig. 1A). Bone marrow cells were isolated and classical CX3CR1-
GFPinter and non-classical CX3CR1-GFPhigh monocytes that were nega-
tive for the bone marrow precursor marker c-kit/CD117, were sorted
by ﬂow cytometry (Fig. 2A). After 4–6 days of culture under pro-
osteoclastogenic conditions in the presence of M-CSF and RANKL,
TRAP+ osteoclasts were counted. While mixed bone marrow cells and
classical CX3CR1-GFPintermonocytes gave rise to osteoclasts, non-classi-
cal CX3CR1-GFPhighmonocytes failed to develop into osteoclasts (Fig. 2B
and C). Bone marrow contains in addition to monocytes also macro-
phages and dendritic cells, which may as well express CX3CR1. In con-
trast, CX3CR1-GFP expression in monocytes of the blood was over 90%
associatedwithmonocytic markers (Supplementary Fig. 1B). We there-
fore used blood from AIA mice for isolating and sorting monocytes to
avoid any contaminations by differentiated macrophages. Consistent
with bone marrow cells, only classical, but not non-classical blood
monocytes differentiated into osteoclasts in vitro (Fig. 2D). The in
vitro condition allowing monocytes to differentiate into osteoclasts
may not fully mimic their respective osteoclastogenic potential in
vivo. Hence, tibiae from the sham control side of CX3CR1-GFP knock-in mice were used for cryosections and the osteoclastogenic character-
istics of the two monocyte subsets were analyzed by co-localization of
endogenous CX3CR1-GFP+ and stained TRAP+ cells in situ. GFP+ bone
marrow cells could clearly be divided into a CX3CR1-GFPinter and
CX3CR1-GFPhigh population.Mature TRAP+ osteoclasts on the bone sur-
face did not express CX3CR1-GFP. However, in the bone marrow cavity
nearby the bone surface, CX3CR1-GFPinter cells were found to be co-lo-
calizedwith TRAP staining, indicating that late TRAP+osteoclast precur-
sor cells show a classical monocyte phenotype (Fig. 2E).
3.3. Anti-TNFα therapy reduces bone lesions and the number of synovial
osteoclasts
To elucidate the precise role of TNFα on bone resorbing osteoclasts
and their precursor cells, we conﬁrmed as a proof of concept that
TNFα contributed to AIA pathogenesis. Arthritis was induced in
TNFR1/2 −/− C57BL/6 mice, lacking both receptors for TNFα. Indeed,
TNFR1/2 −/− C57BL/6 mice showed signiﬁcantly ameliorated arthritis
in terms of synovial inﬂammation and reduced numbers of TRAP+ oste-
oclasts in the knee joint on day 14 of AIA (Supplementary Fig. 2A and B).
To have a clinically more relevant experimental setup, AIA was induced
inWTC57BL/6mice, whichwere from then on treated every secondday
with 10 mg/kg TNFα antagonist, the soluble TNFα receptor etanercept.
Inhibition of TNFα had a bone protective effect, which was reﬂected by
fewer pathological bone lesions (Fig. 3A) and a reduced number of sy-
novial TRAP+ osteoclasts in the knee joint on day 14 of AIA (Fig. 3B).
However, despite the reduced synovial osteoclastogenesis, etanercept
treatedmice still showed highly inﬂamedknee joints thatwere inﬁltrat-
ed with leukocytes (Fig. 3C).
3.4. TNFα blockade reduces the number of synovial Gr-1+ monocytes but
not their recruitment to the arthritic joint
In order to examine if the previously observed bone protective effect
in etanercept treated animals was based on changes in the OPC popula-
tion, myeloid marker expression in different tissues was analyzed by
immunohistochemistry and ﬂow cytometry at acute and chronic
timepoints of AIA. In the acute phase on day 3, knee immunohistochem-
istry of control and etanercept treated mice did not reveal any changes
in terms of the presence of synovial F4/80+ and Gr-1+ myeloid cells. In
line with this, the amount of inﬁltrating CD45high leukocytes in sham
and arthritic knees was not different between both treatment groups
as shown by ﬂow cytometry (Supplementary Fig. 3A and B). Further-
more, neither bone marrow nor blood showed any difference in leuko-
cyte and monocyte numbers between control and etanercept treated
mice on AIA day 3. Only the number of neutrophils was slightly reduced
in the blood of anti-TNFα treated animals on day 3 (Supplementary Fig.
4A and B).
In contrast to day 3, etanercept treatment resulted in clear cellular
changes in the synovial compartment in the early chronic phase on
day 14 of AIA. Although anti-TNFα therapy did not result in any signif-
icant difference in the availability of F4/80+ macrophages (Fig. 4A,
upper panel), etanercept treatment markedly reduced the number of
Gr-1+ cells, a mixed population of neutrophils and Ly6Chigh mono-
cytes/macrophages in the inﬂamed joint (Fig. 4A, lower panel). Since
we previously observed that classical Ly6Chighmonocytes efﬁciently dif-
ferentiated into osteoclasts in vitro, it is noteworthy, that these Ly6C-
highLy6G+ cells were often found in the synovial lining nearby the
bone lesions on the tibial joint surface of control treated mice. Interest-
ingly, arthritic knees of control and etanercept treated animals did not
show any difference in the number of inﬁltrating CD45high leukocytes
(Fig. 4B).
It has been reported that tissue resident cells often show increased
proliferation rates upon inﬂammation and thereby substantially con-
tribute with inﬁltrating cells to the increased amount of synovial cells
[9]. We therefore examined if alterations in local cell proliferation
Fig. 2.Classicalmonocytes showosteoclastogenic properties. A) Classical and non-classicalmonocyteswere sorted byﬂowcytometry using bonemarrow fromheterozygous CX3CR1-GFP
knock-in mice. CX3CR1-GFP vs. CD117 contour plot depicts gates that were used to sort classical CX3CR1-GFPinter and non-classical CX3CR1-GFPhigh monocytes, respectively. B)
Representative pictures of control bone marrow cells (left), sorted classical (center) and non-classical (right) monocytes after 5 days of osteoclastogenic culture. C) Number of
multinucleated TRAP+ osteoclasts/well was counted after 4, 5 and 6 days of cultures and shown as mean + SEM of three samples/replicates from one experiment representative of
three experiments performed. D) Classical and non-classical monocytes were sorted from blood and cultured for 13 days. Number of multinucleated TRAP+ osteoclasts/well was
counted after 13 days of culture and are shown as mean + SEM of three wells/replicates from one experiment. E) Cryosection of undecalciﬁed tibia from one heterozygous CX3CR1-
GFP knock-in mice show CX3CR1-GFP expressing cells (left) and TRAP stained cells (right) which was analyzed for co-localization (arrows). Blue lines depict bone surface. Scale bar
= 100 μm (data shown from a non-arthritic sham knee). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
60 S. Uster et al. / Bone 107 (2018) 56–65contributed to the different knee cellularity observed on day 14 of AIA. A
short-term incorporation of BrdU into dividing synovial cells was done.
Only few tissue resident CD45interCD11b+ macrophages showed some
proliferation, which was, however, not different between the control
and etanercept treatment group. In contrast, inﬁltrating CD45high leuko-
cytes did not show any proliferative properties in control and
Etanercept treated mice and their number was therefore attributable
to their recruitment from blood (Fig. 4C). To address the question if
the lower number of synovial Gr-1+ cells upon anti-TNFα therapy
was based on reduced recruitment of osteoclast precursors into the
joint, an adoptive transfer of monocytes was performed on day 14
after arthritis onset. Bone marrow cells were harvested and enriched
for CD115+ monocytes, then labeled with CSFE and adoptively trans-
ferred into the femoral artery of arthritic mice. After 30 min,periarticular tissue from inﬂamed knees was harvested and analyzed
for inﬁltrating CD45highCD11b+CSFE+ cells by ﬂow cytometry (Fig.
4D, left). The recruitment of adoptively transferred CSFE+ monocytes
into the arthritic kneewas not different between etanercept and control
treated animals supporting the notion that etanercept does not directly
inﬂuence monocyte recruitment into the inﬂamed joint (Fig. 4D, right).
3.5. Anti-TNFα therapy leads to fewer circulating and proliferating mono-
cytic osteoclast precursors in blood and bone marrow, respectively
Since neither synovial inﬂammation nor monocyte recruitment
from blood to synovial tissue was affected by anti-TNFα therapy, we
were wondering if changes in peripheral OPC populations led to fewer
osteoclasts in the inﬂamed joint of etanercept treated mice. We
Fig. 3. Blockade of TNFα by etanercept reduces bone lesions and osteoclasts in the synovial compartment of AIA mice. A) H&E staining shows bone parameters of sham knee (left) and
arthritic knees from control (center) and etanercept (right) treated group from AIA day 14. X (pathological bone lesions). Scale bar = 400 μm. Graphs shows scoring of pathological
bone lesions pooled from three independent experiments (n= 12 mice). B) TRAP staining shows synovial osteoclasts of uninﬂamed sham knee (left) and arthritic knees from control
(center) and etanercept (right) group. Scale bar = 200 μm. Graph depicts scoring for synovial osteoclasts pooled from two independent experiments (n = 8 mice). C) H&E staining
shows synovial inﬂammation and data shown are pooled from three independent experiments (n= 12 mice).➔ (synovial inﬁltrates). Scale bar = 200 μm.
61S. Uster et al. / Bone 107 (2018) 56–65therefore analyzed the cellular composition of bone marrow and blood
by ﬂow cytometry. Indeed, in bone marrow, etanercept treated mice
showed despite unchanged numbers of total CD45+ leukocytes, fewer
Ly6G+ neutrophils and more importantly, fewer proliferating BrdU+
monocyte precursors (Fig. 5A and B). This was accompanied by a dra-
matic reduction of the numbers of circulating monocytes. Etanercept
treated mice harbored fewer circulating classical Ly6Chigh monocytes
and Ly6G+ neutrophils, while the total number of circulating CD45+
leukocytes remained unchanged (Fig. 5C). These data nicely correlated
with the decreased number of Gr-1+ myeloid cells and osteoclasts
found in synovial tissue of etanercept treated animals.3.6. Anti-TNFα therapy does not regulate circulating chemokine levels in ar-
thritic and non-arthritic mice
14 days after onset of arthritis we checked for serum levels of 25 dif-
ferent chemokines (CCL11/eotaxin, CCL12/MCP-5, CCL2/JE/MCP-1,
CCL21/6 Ckine, CCL22/MDC, CCL27/CTACK, CCL28, CCL3/CCL4 (MIP-
1alpha/MIP-1beta), CCL5/RANTES, CCL6/C10, CCL8/MCP-2, CCL9/MIP-1
gamma, Chemerin, Complement Component C%/C5a, CX3CL1/
Fractalkine, CXCL1/KC, CXCL10/IP-10/CRG-2, CXCL11/I-TAC, CXCL12/
SDF-1, CXCL13/BLC/BCA-1, CXCL16, CXCL2/MIP-2, CXCL9/MIG, IL-16,
LIX). Serum levels of mice in the following experimental settings were
checked: non-arthritic controls (n= 4), non-arthritic but etanercept-
treated (n = 4), arthritic (n = 4), arthritic and etanercept-treated (n
=4). However, we found no statistically signiﬁcant differences of circu-
lating chemokine levels. The data are shown in a Supplementary Fig. 5.4. Discussion
In the present study we asked to which degree anti-TNFα therapy
reduces osteoclast mediated bone resorption by affecting osteoclast
precursor cells. We examined if availability of OPCs in bone marrow,
blood and synovia and their recruitment to the arthritic knee was re-
duced upon blockade of TNFα. As a ﬁrst step, we aimed to characterize
themouse osteoclast precursor populations, which belong to themono-
cyte/macrophage lineage. OPCs were previously deﬁned by using gen-
eral monocytic markers, however, the distinction between the two
known classical and non-classical monocyte subpopulations, Ly6C-
highCX3CRinter respectively, was rarely applied [17,19]. Interestingly,
there is increasing evidence that, not only in terms of osteoclastogenic
potential, these monocyte subsets play key roles for different aspects
in RA pathogenesis [8,22,23]. Sorting CX3CR1inter and CX3CR1high
monocytes by ﬂow cytometry from bone marrow and blood showed
that the osteoclastogenic potential was restricted to classical mono-
cytes, which is also supported by ﬁndings in humans [24]. We also
found a difference in the maturation and the number of osteoclasts be-
tween the culture from bonemarrow and blood. We can only speculate
that one probable explanation might be the higher number of macro-
phages and of Ly6high cells in bone marrow compared to blood that
are able to proliferate [25,26]. Moreover, bone marrow contains the
more complex composition of proliferating progenitor cells and ma-
turedmacrophages [27]. This is also reﬂected by the non-homogeneous
cell population in bone marrow compared to the homogeneous cell
population in blood as shown in Supplementary Fig. 1. Classical mono-
cytes are known for their efﬁcient recruitment to the site of infection
Fig. 4.Anti-TNFα therapy reduces number of synovial Gr-1+ cellswithout affecting overallmonocyte recruitment to the arthritic knee in the early chronic phase of arthritis. A) F4/80 (top)
and Gr-1 (bottom) staining shows distribution of synovial macrophages and classical monocytes/neutrophils in sham knee (left) and arthritic knees of the control (center) and the
Etanercept (right) group, respectively. Scale bar = 200 μm. Histological knee scores represent individual observations pooled from two experiments (n = 8 mice). B) Cellularity of
periarticular tissue of sham knees and arthritic knees from AIA day 14 was analyzed by ﬂow cytometry and the number of inﬁltrating CD45high leukocytes all groups was determined.
Numbers of inﬁltrating leukocytes are shown from one experiment (n= 4mice) representative of two experiments performed. C) Local cell proliferation in the synovial compartment
was analyzed by short-term incorporation of BrdU. The graphs depict number of BrdU+ leukocytes within tissue-resident CD45inter (left) and inﬁltrating CD45high (right) leukocytes.
Numbers of BrdU+ leukocytes are shown from one experiment (n = 4 mice) representative of two experiments performed. D) Adoptively transferred CSFE labeled monocytes were
quantiﬁed in periarticular tissues of mice from AIA day 14. Colored gates in the contour plots depict representative percentages of CD11b+CSFE+ cells within CD45high leukocytes of
control and etanercept treated mice, respectively. The number of recruited myeloid cells are pooled from two independent experiments (n= 4mice).
62 S. Uster et al. / Bone 107 (2018) 56–65[6]. Thuswe hypothesized that inﬁltration of circulatingmonocytes into
the arthritic knee is key for newly formed bone lesions by giving rise to
bone resorbing osteoclasts in the arthritic joint. In accordance with this,
it has been shown in parabiosis experiments that circulating GFP+
monocytes from CX3CR1-GFP knock-in mice differentiated into mature
GFP+ osteoclasts in bone tissue of WT mice [28]. However, we also de-
tected over the course of AIA low numbers of proliferating tissue resi-
dent CD45inter macrophages in inﬂamed and non-inﬂamed knees. We
cannot fully exclude that these tissue resident macrophages might
also give rise to osteoclasts in ourmodel. However, tissue residentmac-
rophages are known for their speciﬁc tissue-related tasks and theirmature phenotype, which argues against their plasticity as OPCs [9,
10]. Having deﬁned themonocytic OPC population,wewerewondering
if the observedboneprotective effect upon anti-TNFα therapy can be at-
tributed to reduced recruitment of circulating monocytes to the in-
ﬂamed knee. TNFα and other inﬂammatory cytokines are key effector
molecules regulating leukocyte migration as they efﬁciently upregulate
endothelial cell adhesion molecules at the site of inﬂammation [29].
Surprisingly, the recruitment of adoptively transferred monocytes into
the inﬂamed knee was not different between control and etanercept
treated mice, which might be explained by the still strong on-going in-
ﬂammation in the knee at this timepoint of arthritis in our model. In
Fig. 5. Anti-TNFα therapy with Etanercept reduces the number of circulating classical monocytes and neutrophils and number of neutrophils and proliferating monocyte precursors in
bone marrow. A) Local cell proliferation in the bone marrow compartment was analyzed by short-term incorporation of BrdU. Contour plots show representative percentages of
BrdU+ cells within CD115+Ly6Chigh monocytes of control and etanercept group, respectively. Number of BrdU incorporated cells within CD115+Ly6Chigh monocytes was determined
in one experiment (n = 4 mice). B) CD45+ leukocyte, Ly6G+ neutrophil and classical Ly6Chigh monocyte number in the bone marrow was determined and data shown are from one
experiment (n = 4 mice). C) Graphs represent number of circulating CD45+ leukocytes, Ly6G+ neutrophils and classical Ly6Chigh in the blood of control and etanercept treated mice
on AIA day 14. Data shown are pooled from three independent experiments (n= 12 mice).
63S. Uster et al. / Bone 107 (2018) 56–65accordance with this, the number of inﬁltrated CD45high leukocytes and
the synovial inﬂammation in knees of etanercept treatedmicewere not
reduced on day 14 post knee-injection.
Similar to RA patients, who showed bone protection irrespective of
the clinical response (pain and joint swelling), to anti-TNF therapy
[18,30], we found lower numbers of osteoclasts and bone lesions in
still inﬂamed joints. In contrast, by MicroCT analyses we saw no differ-
ences in cortical and trabecular volumes and densities in knees from
AIA control and etanercept treated mice. One explanation could be
that the time point of 14 days after induction of AIA was too early for
morphometric bone analysis to detect signiﬁcant differences in AIA
with and without anti-TNF treatment. However, our data demonstrate
that TNFα inhibition affects synovial osteoclastogenesis beyond the sy-
novial compartment in the arthritic joint. Indeed, we showed that TNFα
inhibition critically reduced the pool of proliferating bone marrow
monocytic OPCs. This observation is in linewith other studies, which re-
ported that absence of TNFα reduced the number of immature myeloid
cells in the bone marrow [31]. Even more impressive was the marked
reduction of circulating classical monocytes in the blood of etanercepttreated mice on day 14 after arthritis onset. One possible explanation
for their lower number in blood would be cell death. However,
inﬂiximab treated RA patients did not show any signs of apoptosis in pe-
ripheral blood monocytes [32]. More likely, TNFα seemed to diminish
the pool of circulating OPCs by ﬁrst affecting monocytic precursor cells
in bone marrow leading to a subsequently reduced number of mono-
cytes released into blood. This assumption is ﬁnally in line with our ob-
servations that treatment with etanercept markedly reduced the
number of Gr-1+ cells, a mixed myeloid population of neutrophils and
Ly6Chigh monocytes/macrophages in the inﬂamed joint and that classi-
cal Ly6Chigh monocytes efﬁciently differentiated into osteoclasts in
vitro and were often found in the synovial lining nearby the bone le-
sions on the tibial joint surface of control treated mice. Although we
cannot exclude that etanercept additionally reduced osteoclast-induc-
ing pro-inﬂammatory cytokine expression in the joint, we could clearly
demonstrate a concordant decrease of OPCs of myeloid origin in bone
marrow, peripheral blood and in the inﬂamed synovial tissue upon
anti-TNFα treatment of arthritic mice. In light of our observations that
adoptively transferred monocytes home equally well to the inﬂamed
64 S. Uster et al. / Bone 107 (2018) 56–65joints of etanercept and sham treated mice our data strongly suggest
that etanercept reduced monocyte supply from bone marrow rather
than monocyte migration into the joint.
In accordance with this, TNFα was shown to reduce expression of
CXCL12 in the bone marrow, which led to OPC release into the blood
[33]. Moreover, our results also nicely correspond to the rapid decline
in the number of circulating classical monocytes, the reduced expres-
sion of CXC chemokine receptor 4, C-C chemokine receptor type 2 and
circulating stromal cell-derived factor-1 observed in patients with RA
responding to anti-TNFα treatment with inﬂiximab [34]. However,
this could not be observed in our experimental AIA setting. 14 days
after arthritis onset treatmentwith etanercept did not change the levels
of circulating chemokines. Either this time period of ongoing arthritis
was still too short to ﬁnd any signiﬁcant regulation of chemokines
that could explain the downregulation of the number of circulating clas-
sical monocytes and neutrophils or the reduced peripheral cell numbers
did merely reﬂect the failing supply from bone marrow.
The missed chemokine regulation upon etanercept treatment also
makes it less probable that altered proinﬂammatory cytokine proﬁle
was responsible for reduced numbers of circulating classical monocytes
and neutrophils, although we cannot exclude that anti-TNFα treatment
might have affected immune cells in lymph nodes such as Th17 cells
that are associatedwith neutrophil accumulation and chemokine recep-
tor expression.
Overall, the current study demonstrates that the bone protective ef-
fect mediated by blocking TNFα does not seem to mainly depend on di-
rect inhibition of the synovial inﬂammation in the arthritic joint but
may rather rely on limitingOPC supply from the bonemarrow, thus lim-
iting the number of monocytes circulating in the blood and able to mi-
grate into the arthritic joint.
5. Limitations
Our study had several limitations. First, our experimental approach
did not allow to directly correlate OPC numbers in different compart-
ments with the synovial osteoclastogenesis. Second, the number of ex-
periments showing the reduction of proliferating bone marrow
monocyte precursors was relatively low to draw deﬁnite conclusions.
Third, we did not correlate the number of osteoclastogenic cells in the
synovial compartment with alterations of synovial inﬂammatory cyto-
kine milieu upon anti-TNFα treatment that could have inﬂuenced di-
rected cellular inﬂux although synovial inﬂammation was still ongoing
despite reduced synovial osteoclastogenesis and reduced bone destruc-
tion. Fourth, we did not discern if AIA treatment with etanercept did af-
fect immune cells in local lymph nodes such as Th17 which might be
associated with neutrophil accumulation and chemokine receptor
expression.
6. Conclusion
Although being largely descriptive, our ﬁndings indicate that anti-
TNFα treatment with etanercept had a bone protective effect in AIA of
themouse. This effectwas notmerely a consequence of downregulation
of the inﬂammatory synovial response but coincided with the simulta-
neous reduction of numbers of osteoclast precursor cells in bone mar-
row, blood and synovial tissue and therefore suggested a reduced
supply from the bonemarrow. Our data point to the necessity of subse-
quent studies using cell tracking approaches to follow up the fate of
bone marrow and blood OPCs over the entire course of arthritis [35].
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.bone.2017.10.020.
Acknowledgements
We acknowledge Dr. Israel F Charo (Gladstone Institute of Cardio-
vascular Research, University of California, San Francisco, USA) and Dr.Richard Ransohoff (Biogen Idec, Cambridge, MA, USA) for graciously
providing the CX3CR1-GFP knock-inmice.We thank Silvia Dolder, Irena
Klima, Mark Siegrist, Heidi Tardent, Regina Reissmann, Dr. Juliana
Barreto deAlbuquerque andAntoinetteWetterwald for expert technical
assistance and the animal caretakers Katrin Bisseger, Irina Geiger and
Svetolzar Tsonev for excellent care of the animals. We also thank
Matthias Hedinger from the Department of Biochemistry for letting us
use his equipment for analysing the serum chemokine blots. Last but
not least we thankDr. UrbanDeutsch for expertmanaging of ourmouse
colonies according to the 3R rules.
Conﬂict of interest
The authors declare no ﬁnancial or commercial conﬂict of interest.
Funding
This study was funded by the Swiss National Science Foundation
grant 310030_138459 to MS, BE, JVS, DA andWH, by the scientiﬁc fund
of the Department of Rheumatology, Immunology & Allergology, Uni-
versity Hospital of Bern, Switzerland, and by the SNSF and
Swissuniversities funded ProDoc „Cell Migration “to BE and JVS. SU
was enrolled in the Graduate School for Biomedical and Cellular Sci-
ences of the University of Bern.
All procedureswere performed in accordancewith the Swiss legisla-
tion on the protection of animals andwere approved under the applica-
tion number BE 18/12 and BE 55/15 by the veterinary ofﬁce of the
Canton of Bern.
Authors contributions
SU performed and analyzed all experiments and wrote the manu-
script. FMC contributed to AIA experiments and analysis and contribut-
ed to writing the manuscript. DA, JVS, WH, BE and MS designed and
supervised the study and were involved in drafting the article or revis-
ing it critically for important intellectual contents; MS and BE have full
access to all of the data in the study and take responsibility for the integ-
rity of the data and the accuracy of the data analysis. All authors declare
their consent for publication of this manuscript.
References
[1] I.B. McInnes, G. Schett, The pathogenesis of rheumatoid arthritis, N. Engl. J. Med. 365
(23) (2011) 2205–2219.
[2] G. Kollias, P. Papadaki, F. Apparailly, M.J. Vervoordeldonk, R. Holmdahl, V. Baumans,
C. Desaintes, et al., Animal models for arthritis: innovative tools for prevention and
treatment, Ann. Rheum. Dis. 70 (8) (2011) 1357–1362.
[3] T. Suda, I. Nakamura, E. Jimi, N. Takahashi, Regulation of osteoclast function, J. Bone
Miner. Res. 12 (6) (1997) 869–879.
[4] G. Karsenty, The genetic transformation of bone biology, Genes Dev. 13 (23) (1999)
3037–3051.
[5] M.M. Tondravi, et al., Osteopetrosis in mice lacking haematopoietic transcription
factor PU.1, Nature 386 (6620) (1997) 81–84.
[6] F. Geissmann, S. Jung, D.R. Littman, Bloodmonocytes consist of two principal subsets
with distinct migratory properties, Immunity 19 (1) (2003) 71–82.
[7] F. Ginhoux, S. Jung, Monocytes and macrophages: developmental pathways and tis-
sue homeostasis, Nat. Rev. Immunol. 14 (6) (2014) 392–404.
[8] Alexander V. Misharin, Carla M. Cuda, Rana Saber, Jason D. Turner, Angelica K.
Gierut, G. Kenneth Haines, Sergejs Berdnikovs, et al., Nonclassical Ly6c−monocytes
drive the development of inﬂammatory arthritis in mice, Cell Rep. 9 (2) (2014)
591–604.
[9] L.C. Davies, et al., A quantiﬁable proliferative burst of tissue macrophages restores
homeostatic macrophage populations after acute inﬂammation, Eur. J. Immunol.
41 (8) (2011) 2155–2164.
[10] D. Hashimoto, A. Chow, C. Noizat, P. Teo, M.B. Beasley, M. Leboeuf, C.D. Becker, et al.,
Tissue-resident macrophages self-maintain locally throughout adult life with mini-
mal contribution from circulating monocytes, Immunity 38 (4) (2013) 792–804.
[11] K. Redlich, J.S. Smolen, Inﬂammatory bone loss: pathogenesis and therapeutic inter-
vention, Nat. Rev. Drug Discov. 11 (3) (2012) 234–250.
[12] Z. Yao, P. Li, Q. Zhang, E.M. Schwarz, P. Keng, A. Arbini, B.F. Boyce, L. Xing, Tumor ne-
crosis factor-alpha increases circulating osteoclast precursor numbers by promoting
their proliferation and differentiation in the bone marrow through up-regulation of
C-Fms expression, J. Biol. Chem. 281 (17) (2006) 11846–11855.
65S. Uster et al. / Bone 107 (2018) 56–65[13] C.K. Lee, E.Y. Lee, S.M. Chung, S.H. Mun, B. Yoo, H.B. Moon, Effects of disease –mod-
ifying antirheumatic drugs and anti-inﬂammatory cytokines on human osteoclasto-
genesis through interaction with receptor activator of nuclear factor kappa B,
osteoprotegerin, and receptor activator of nuclear factor kappa B ligand, Arthritis
Rheum. 50 (12) (2004) 3831–3843.
[14] K. Redlich, B. Gortz, S. Hayer, J. Zwerina, N. Doerr, P. Kostenuik, H. Bergmeister, et al.,
Repair of local bone erosions and reversal of systemic bone loss upon therapy with
anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hor-
mone in tumor necrosis factor-mediated arthritis, Am. J. Pathol. 164 (2) (2004)
543–555.
[15] H. Marotte, P. Miossec, Prevention of bone mineral density loss in patients with
rheumatoid arthritis treated with anti-TNFalpha therapy, Biologics 2 (4) (2008)
663–669.
[16] C.T. Ritchlin, S.A. Haas-Smith, P. Li, D.G. Hicks, E.M. Schwarz, Mechanisms of TNFα –
and RANKL –mediated osteoclastogenesis and bone resorption in psoriatic arthritis,
J. Clin. Invest. 111 (6) (2003) 821–831.
[17] P. Li, E.M. Schwarz, R.J. O'Keefe, L. Ma, B.F. Boyce, L. Xing, Rank signaling is not re-
quired for Tnfalpha-mediated increase in Cd11(Hi) osteoclast precursors but is es-
sential for mature osteoclast formation in Tnfalpha-mediated inﬂammatory
arthritis, J. Bone Miner. Res. 19 (2) (2004) 207–213.
[18] J.S. Smolen, C. Han, M. Bala, R.N. Maini, J.R. Kalden, D. van der Heijde, F.C. Breedveld,
D.E. Furst, P.E. Lipsky, ATTRACT Study Group, Evidence of radiographic beneﬁt of
treatment with inﬂiximab plus methotrexate in rheumatoid arthritis patients who
had no clinical improvement: a detailed subanalysis of data from the anti-tumor ne-
crosis factor trial in rheumatoid arthritis with concomitant therapy study, Arthritis
Rheum. 52 (4) (2005) 1020–1030.
[19] M. Ishii, J.G. Egen, F. Klauschen,M.Meier-Schellersheim, Y. Saeki, J. Vacher, R.L. Proia,
R.N. Germain, Sphingosine-1-phosphate mobilizes osteoclast precursors and regu-
lates bone homeostasis, Nature 458 (7237) (2009) 524–528.
[20] D. Brackertz, G.F. Mitchell, I.R. Mackay, Antigen-induced arthritis in mice. I. Induc-
tion of arthritis in various strains of mice, Arthritis Rheum. 20 (3) (1977) 841–850.
[21] X. Jiang, Z. Kalajzic, P. Maye, A. Braut, J. Bellizzi, M. Mina, D.W. Rowe, Histological
analysis of GFP expression in murine bone, J. Histochem. Cytochem. 53 (5) (2005)
593–602.
[22] H. Bruhl, J. Cihak, J. Plachy, L. Kunz-Schughart, M. Niedermeier, A. Denzel, M.
Rodriguez Gomez, et al., Targeting of Gr-1+,Ccr2+monocytes in collagen-induced
arthritis, Arthritis Rheum. 56 (9) (2007) 2975–2985.
[23] T. Nanki, Y. Urasaki, T. Imai, M. Nishimura, K. Muramoto, T. Kubota, N. Miyasaka, In-
hibition of Fractalkine ameliorates murine collagen-induced arthritis, J. Immunol.
173 (11) (2004) 7010–7016.
[24] Y. Komano, T. Nanki, K. Hayashida, K. Taniguchi, N. Miyasaka, Identiﬁcation of a
human peripheral blood monocyte subset that differentiates into osteoclasts, Ar-
thritis Res. Ther. 8 (2006) R152.[25] D.R. Engel, J. Maurer, A.P. Tittel, C. Weiheit, T. Cavlar, B. Schmak, A. Limmer, N. van
Rooijen, C. Trautwein, F. Tacke, C. Kurts, CCR2 mediates homeostatic and inﬂamma-
tory release of Gr1 (high) monocytes from the bone marrow, but is dispensable for
bladder inﬁltration in bacterial urinary tract infection, J. Immunol. 181 (8) (2008)
5579–5586.
[26] M. Rosas, B. Thomas, M. Stacey, S. Gordon, P.R. Taylor, The myeloid 7/4-antigen de-
ﬁnes recently generated inﬂammatorymacrophages and is synonymouswith Ly-6B,
J. Leukoc. Biol. 88 (1) (2010) 169–180.
[27] J. Hettinger, D.M. Richards, J. Hansson, M.M. Barra, A.C. Joschko, J. Krijgsveld, M.
Feuerer, Origin of monocytes and macrophages in a committed progenitor, Nat.
Immunol. 14 (2013) 821–830.
[28] M. Kotani, J. Kikuta, F. Klauschen, T. Chino, Y. Kobayashi, H. Yasuda, K. Tamai, et al.,
Systemic circulation and bone recruitment of osteoclast precursors tracked by using
ﬂuorescent imaging techniques, J. Immunol. 190 (2) (2013) 605–612.
[29] P.P. Tak, P.C. Taylor, F.C. Breedveld, T.J. Smeets, M.R. Daha, P.M. Kluin, A.E. Meinders,
R.N. Maini, Decrease in cellularity and expression of adhesion molecules by anti-
tumor necrosis factor α monoclonal antibody treatment in patients with rheuma-
toid arthritis, Arthritis Rheum. 39 (7) (1996) 1077–1081.
[30] M. Hoff, T.K. Kvien, J. Kälvesten, A. Elden, A. Kavanaugh, G. Haugeberg, Adalimumab
reduces hand bone loss in rheumatoid arthritis independent of clinical response:
subanalysis of the PREMIER study, BMC Musculoskelet. Disord. 12 (2011) 54.
[31] M. Sade-Feldman, J. Kanterman, E. Ish-Shalom,M. Elnekave, E. Horwitz, M. Baniyash,
Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activ-
ity of immature myeloid cells during chronic inﬂammation, Immunity 38 (3) (2013)
541–554.
[32] C.A. Wijbrandts, P.H. Remans, P.L. Klarenbeek, D. Wouters, M.A. van den Bergh
Weerman, T.J. Smeets, M.J. Vervoordeldonk, D. Baeten, P.P. Tak, Analysis of apopto-
sis in peripheral blood and synovial tissue very early after initiation of inﬂiximab
treatment in rheumatoid arthritis patients, Arthritis Rheum. 58 (10) (2008)
3330–3339.
[33] Q. Zhang, R. Guo, E.M. Schwarz, B.F. Boyce, L. Xing, Tnf inhibits production of stromal
cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobi-
lization from bone marrow to peripheral blood, Arthritis Res. Ther. 10 (2008) R37.
[34] D. Aeberli, R. Kamgang, D. Balani, W. Hofstetter, P.M. Villiger, M. Seitz, Regulation of
peripheral classical and non-classical monocytes on inﬂiximab treatment in patients
with rheumatoid arthritis and ankylosing spondylitis, RMD Open 2 (1) (2016),
e000079. .
[35] F.H. Shand, S. Ueha, M. Otsuji, S.S. Koid, S. Shichino, T. Tsukui, M. Kosugi-Kanaya,
et al., Tracking of intertissue migration reveals the origins of tumor-inﬁltrating
monocytes, Proc. Natl. Acad. Sci. U. S. A. 111 (21) (2014) 7771–7776.
